Brief: Panbela Announces Paces S0820 Phase Iii Trial Passes Pre-Planned Futility Analysis
28/06/2023 14:10
June 28 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA ANNOUNCES PACES S0820 PHASE III TRIAL PASSES
PRE-PLANNED
FUTILITY ANALYSIS
Source text for Eikon: ID:nGNX4gM6rs
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants